Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GSK plc has announced the purchase of 547,800 of its own ordinary shares, as part of its ongoing buyback program, through its broker Citigroup Global Markets Limited. This transaction, executed on March 4, 2025, is part of a non-discretionary agreement and reflects the company’s strategy to manage its capital structure, potentially impacting shareholder value and market perception.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company operating in the pharmaceutical industry, focusing on the development and production of medicines, vaccines, and consumer healthcare products.
YTD Price Performance: 10.14%
Average Trading Volume: 7,985,177
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £59.81B
See more data about GSK stock on TipRanks’ Stock Analysis page.